Search Results

QIAGEN announced that it welcomes new guidelines in the United States that recommend screening at-risk children of all ages for latent tuberculosis infection with modern blood-based tests such as QIAGEN’s market-leading QuantiFERON-TB Gold Plus.

A new tuberculosis test disclosed in the Association for Diagnostics & Laboratory Medicine’s Clinical Chemistry journal would allow testing for TB treatment monitoring to occur outside of a biosafety level 3 laboratory.

IAVI today announced that the Bill & Melinda Gates Foundation has awarded IAVI US$55 million to conduct a Phase IIb trial assessing the safety and efficacy of the tuberculosis (TB) vaccine candidate MTBVAC to prevent active TB lung disease in adolescents and adults.

TB Alliance welcomes Kim Schwartz and Rasha Hibri to its Board of Directors. Their expertise will help guide the organization as it continues to advance its research and product delivery agenda.

ProteinLogic announced that they have received a $1.35 million grant from the Bill & Melinda Gates Foundation to accelerate the development of ImmiPrint® Technology to monitor treatment responses to TB antimicrobial chemotherapy.

With Johnson and Johnson recently granting permission to Stop TB Partnership to distribute its generic TB drug bedaquiline to the majority of low- and middle-income countries, AIDS Healthcare Foundation applauds Stop TB Partnership and the TB community overall for their strong leadership and advocacy in inking this vital agreement.